Healthcare Sales & Marketing Network News: tardive dyskinesia

Searching News Database: tardive dyskinesia

HSMN NewsFeed - 6 Apr 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Apr 2025
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 20 Dec 2024
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY(TM) (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Biopharmaceuticals Product Launch

HSMN NewsFeed - 27 Apr 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 24 Jul 2018
AbbVie Receives U.S. FDA Approval of ORILISSA(TM) (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 5 Oct 2017
Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 21 Apr 2017
Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Biopharmaceuticals Neurology

HSMN NewsFeed - 30 Nov 2016
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 25 Oct 2016
ANI Pharmaceuticals Announces Launch of Benztropine Mesylate Tablets USP
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 11 Oct 2016
Neurocrine Announces INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 2 Feb 2016
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Nov 2015
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 13 Mar 2015
Actavis Receives FDA Approval of SAPHRIS(R) for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 17 Oct 2013
Auspex Appoints Pratik Shah as CEO and Expands Executive Team
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 23 Apr 2013
FDA Approves Second Drug in BD Simplist(TM) Prefilled Injectable Line of Products
Biopharmaceuticals Devices Drug Delivery Generics FDA

HSMN NewsFeed - 8 Nov 2012
Auspex Pharmaceuticals Closes $25 Million Series D Financing
Biopharmaceuticals Neurology Venture Capital Personnel

HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals

HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Nov 2009
Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Biopharmaceuticals

HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 18 May 2009
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
Biopharmaceuticals Neurology Acquisitions

HSMN NewsFeed - 27 Apr 2009
RISPERDAL CONSTA Approved in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2009
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Feb 2009
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Feb 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Biopharmaceuticals

HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Oct 2008
Eli Lilly and Company Resolves Investigation Involving Numerous States
Biopharmaceuticals

HSMN NewsFeed - 26 Sep 2008
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals

HSMN NewsFeed - 7 May 2008
Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Biopharmaceuticals

HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Biopharmaceuticals

HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Biopharmaceuticals

HSMN NewsFeed - 28 Feb 2008
FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Feb 2008
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Nov 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Oct 2007
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals

HSMN NewsFeed - 7 Sep 2007
Statement of Eli Lilly and Company on Dr. David Egilman Settlement
Biopharmaceuticals Litigation

HSMN NewsFeed - 22 Aug 2007
FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 21 Jun 2007
FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA

HSMN NewsFeed - 18 May 2007
FDA Approves Astrazeneca's Once-Daily Seroquel XR(TM) Extended-Release Tablets for the Treatment of Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Biopharmaceuticals

HSMN NewsFeed - 1 Mar 2007
FDA Grants Pediatric Exclusivity for RISPERDAL(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Feb 2007
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
Biopharmaceuticals Litigation

HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Biopharmaceuticals

HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Biopharmaceuticals Litigation

HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Dec 2006
INVEGA(TM) Approved By FDA as New Treatment for Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals

HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Biopharmaceuticals

HSMN NewsFeed - 20 Oct 2006
FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression Treatment
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Jul 2006
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
Biopharmaceuticals FDA

HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Second Investigational Study of SEROQUEL(R) in the Treatment of Depressive Episodes Associated with Bipolar Disorder Confirms Previous Findings
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals

HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Biopharmaceuticals

HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals

HSMN NewsFeed - 16 May 2006
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
Biopharmaceuticals

Return to NewsFeed

Additional items found! 46

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 46 additional stories matching:
tardive dyskinesia
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!